Latest Hotspot

FDA Approves GT Biopharma's IND Application for GTB-3650 in CD33+ Leukemia Therapy

3 July 2024
3 min read

GT Biopharma, Inc., a clinical-stage immuno-oncology firm dedicated to the creation of advanced therapies using its unique natural killer cell engager, the TriKE platform, has revealed that the FDA has approved its IND application for GTB-3650. This approval permits the company to initiate a Phase 1 clinical trial, which is expected to begin in the latter half of 2024.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

"The FDA clearance for GTB-3650 is a significant milestone, and we are eager to submit our next Investigational New Drug (IND) application in the first quarter of 2025 for GTB-5550, which aims to target multiple solid tumors," stated Michael Breen, Executive Chairman and Interim Chief Executive Officer of GT Biopharma.

"As we advance our clinical operations, we intend to initiate the Phase 1 trial for GTB-3650 within the next few months, with several data releases anticipated in 2025. Additionally, we plan to commence a basket trial using GTB-5550 for multiple solid tumors in 2025. We remain highly optimistic about exploring further prospects for various autoimmune conditions where our TriKEs could offer therapeutic benefits," Breen elaborated.

The Phase 1 dose-escalation study will assess GTB-3650 in up to six cohorts of adult patients with relapsed or refractory hematologic malignancies expressing CD33, such as acute myeloid leukemia and high-risk myelodysplastic syndrome. The dosing regimen for GTB-3650 will involve two-week cycles, administered for two weeks followed by a two-week break, extending up to four months based on observed clinical benefits. The trial aims to evaluate safety parameters, pharmacokinetics, pharmacodynamics, in vivo expansion of endogenous patient NK cells, and overall clinical activity.

"GTB-3650 is engineered to target NK cells in the immune system to potentially address the limitations of current AML chemotherapies," said Breen. "Our trial design is expected to provide initial insights into safety and possible therapeutic effects, as well as valuable information that will shape our clinical development plans for future TriKE molecules, including GTB-5550."

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of July 3, 2024, there are 109 investigational drugs for the CD33 target, including 39 indications, 99 R&D institutions involved, with related clinical trials reaching 186, and as many as 29027 patents.

OXS-C3550 is an immune stimulating antibody conjugate drug with a specific focus on targeting CD16a x CD33 x IL15R in the treatment of neoplasms, hemic, and lymphatic diseases, particularly acute myeloid leukemia and myelodysplastic syndromes. Developed by the University of Minnesota, the drug has received IND approval, marking an important step in its journey towards potential clinical use. 

图形用户界面, 文本, 应用程序

描述已自动生成

Is Triheptanoin approved by the FDA?
Drug Insights
3 min read
Is Triheptanoin approved by the FDA?
3 July 2024
The U.S. Food and Drug Administration (FDA) approved Dojolvi on June 30, 2020, for the treatment of long-chain fatty acid oxidation disorders (LC-FAODs) in adults and children.
Read →
Initial Disease-Free Survival Results from Phase 1a ELI-002 7P AMPLIFY-7P Study by Elicio Therapeutics
Latest Hotspot
3 min read
Initial Disease-Free Survival Results from Phase 1a ELI-002 7P AMPLIFY-7P Study by Elicio Therapeutics
3 July 2024
Elicio Therapeutics Presents Initial Disease-Free Survival Data from the Phase 1a AMPLIFY-7P Study of ELI-002 7P.
Read →
Is Phesgo approved by the FDA?
Drug Insights
3 min read
Is Phesgo approved by the FDA?
3 July 2024
The U.S. Food and Drug Administration (FDA) approved Phesgo on June 29, 2020, for the treatment of HER2-positive breast cancer.
Read →
Ensho Therapeutics Debuts with Oral α4β7 Inhibitor for Phase 2 Trials in IBD
Latest Hotspot
3 min read
Ensho Therapeutics Debuts with Oral α4β7 Inhibitor for Phase 2 Trials in IBD
3 July 2024
Ensho Therapeutics revealed that it has secured a portfolio of oral α4β7 integrin inhibitors under an exclusive global license agreement with EA Pharma Co., Ltd., a division of Eisai Co., Ltd.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.